Performance
AvgPrice return has been average, nothing exciting
Valuation
HighSeems to be overvalued vs the market average
Growth
LowLagging behind the market in financials growth
Profitability
AvgAverage profitability - not good, not bad
Entry point
AvgThe stock is overpriced but is not in the overbought zone
Red flags
AvgThe stock has a moderate number of red flags
How to use scorecard? Learn more
Strides Pharma Science is a vertically integrated global pharmaceutical company engaged in the development and manufacturing of active pharmaceutical ingredients and formulations, as well as biotech
Customise key metrics, see detailed forecasts, download stock data and more
A significant proportion of promoter holdings is pledged
In last 3 months, mutual fund holding of the company has almost stayed constant
1 week ago•Bloomberg Quint
1 week ago•Moneycontrol
1 week ago•Moneycontrol
Strides Pharma Science Limited has informed the Exchange regarding a press release dated April 09, 2024, titled "Strides receives USFDA approval for Fluoxetine Tabs 10 mg and 20 mg". | Download
Strides Pharma Science Limited has informed the Exchange regarding a press release dated April 09, 2024, titled "Strides receives USFDA approval for Fluoxetine Tabs 10 mg and 20 mg". | Download
Final • Div/Share: ₹ 1.5
Total Promoter HoldingIncreasing promoter holding is considered good and reflects management’s positive view about the future outlook
In last 6 months, promoter holding in the company has almost stayed constant